跳至主要内容
临床试验/NCT02364297
NCT02364297Unknown不适用

Efficacy of Early-TIPS in the Treatment of Acute Variceal Bleeding From Gastric Fundal Varices: a RCT vs Standard Therapy

Institut d'Investigacions Biomèdiques August Pi i Sunyer5 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2015年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
60
试验地点
5
主要终点
Combined: Absence of rebleeding + survival

研究概览

简要总结

In the last years, important advances have been done in the treatment and prevention of fundal variceal bleeding in patients with cirrhosis. Experts agree that the combination of pharmacological and endoscopic therapy (with tissue adhesives) should be the first line therapy in the acute bleeding episode from isolated gastric varices (IGV1) or type 2 gastroesophageal varices (GOV2) varices; whereas transjugular intrahepatic portosystemic shunt (TIPS) is considered a rescue therapy. TIPS has been shown to effectively prevent variceal rebleeding but with a potential increase in the incidence of hepatic encephalopathy and/or liver failure. In this sense, a recent randomized controlled trial (RCT) in esophageal variceal bleeding showed that an early TIPS, performed during the first 72h after patient admission resulted in a significant decrease in failure to control bleeding and early and late rebleeding. Moreover, survival was also significantly increased as well as other portal-hypertension related complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, etc).

The present study is directed at comparing the outcome of patients with acute bleeding from fundal varices (IGV1 or GOV2) treated by standard therapy (vasoactive drugs + endoscopic injection of tissue adhesives) with or without early TIPS (performed during the first 1-5 days after admission). Main end-point will be survival free of variceal rebleeding at 1 year from inclusion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients developing acute variceal bleeding from GOV2 and/or IGV1 defined according to Baveno II criteria, admitted in the Hospital and receiving standard combined medical therapy (somatostatin 3 mg/12h continuous IV infusion or terlipressin, 2mg/4h IV + endoscopic injection of tissue adhesives as per center protocol).

排除标准

  • •Hepatocarcinoma without therapeutic options (according to Milan criteria).
  • •Portal or mesenteric vein thrombosis avoiding the performance of TIPS.
  • •Acute alcoholic hepatitis.
  • •Platelet count < 20.000/mm
  • •Previous treatment with portosystemic shunt.
  • •Pregnancy.
  • •Previous inclusion in the current study.
  • •Terminal liver disease (bilirrubin > 10 mg/dL and/or prothrombin index < 30%); or other fatal non-liver diseases.
  • •Denied informed consent.

研究组 & 干预措施

Early TIPS

Active Comparator

Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.

Performance of TIPS in the first 5 days following acute gastric variceal bleeding.

干预措施: Early TIPS (Device)

Control

Placebo Comparator

Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.

Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices).

干预措施: Early TIPS (Device)

结局指标

主要结局

Combined: Absence of rebleeding + survival

时间窗: 1 year

The primary endpoint combines absence of rebleeding + survival during the first 1 year after inclusion in the study. Patients to compare are those with liver cirrhosis and acute bleeding from IGV1 or GOV2 varices initially treated with combined pharmacological and endoscopic therapy. Those patients will be randomized to receive a TIPS or standard medical therapy (pharmacological + endoscopic injection of tissue adhesives)

次要结局

  • Transfusional requirements(6 weeks and 1 year)
  • Hospital stay(1 year)
  • Use of hospital resources(1 year)
  • Absence of portal hypertension-related complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome)(6 weeks and 1 year)
  • Individual adverse events(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Àngels Escorsell

Senior Consultant

Institut d'Investigacions Biomèdiques August Pi i Sunyer

研究点 (5)

Loading locations...

相似试验